Bio-Reference Laboratories Company Profile (NASDAQ:BRLI)

About Bio-Reference Laboratories (NASDAQ:BRLI)

Bio-Reference Laboratories logoBio-Reference Laboratories, Inc. is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It is focused on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology and other tissue analysis. It operates a clinical knowledge management service through its PSIMedica business unit. It also operates a Web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. Its laboratory testing business consists of routine testing and esoteric testing.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Health Care Services
  • Symbol: NASDAQ:BRLI
  • CUSIP: 09057G60
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $41.81
  • 200 Day Moving Avg: $36.97
  • 52 Week Range: $26.32 - $47.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 14.98
  • P/E Growth: 0.00
Misc:
  • Average Volume: 653,202 shs.
 

Frequently Asked Questions for Bio-Reference Laboratories (NASDAQ:BRLI)

What is Bio-Reference Laboratories' stock symbol?

Bio-Reference Laboratories trades on the NASDAQ under the ticker symbol "BRLI."

How were Bio-Reference Laboratories' earnings last quarter?

Bio-Reference Laboratories Inc (NASDAQ:BRLI) released its quarterly earnings data on Thursday, December, 18th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.63 by $0.03. The firm earned $227.60 million during the quarter, compared to analysts' expectations of $228.81 million. Bio-Reference Laboratories's revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.40 EPS. View Bio-Reference Laboratories' Earnings History.

Who are some of Bio-Reference Laboratories' key competitors?

How do I buy Bio-Reference Laboratories stock?

Shares of Bio-Reference Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bio-Reference Laboratories stock cost?

One share of Bio-Reference Laboratories stock can currently be purchased for approximately $34.61.

Analyst Ratings

Consensus Ratings for Bio-Reference Laboratories (NASDAQ:BRLI) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Bio-Reference Laboratories (NASDAQ:BRLI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Bio-Reference Laboratories (NASDAQ:BRLI)
Earnings by Quarter for Bio-Reference Laboratories (NASDAQ:BRLI)
Earnings History by Quarter for Bio-Reference Laboratories (NASDAQ:BRLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/8/2015Q215$0.46$0.38$227.33 million$224.00 millionViewListenView Earnings Details
3/5/2015Q115$0.36$0.24$216.40 million$209.00 millionViewListenView Earnings Details
12/18/2014Q414$0.63$0.66$228.81 million$227.60 millionViewListenView Earnings Details
8/27/2014Q314$0.53$0.55$210.44 million$222.10 millionViewListenView Earnings Details
6/5/2014Q214$0.32$0.37$0.20 million$201.30 millionViewListenView Earnings Details
3/4/2014Q114$0.14$0.11$175.52 million$181.30 millionViewListenView Earnings Details
12/19/2013Q4$0.40$0.40$188.96 million$192.20 millionViewListenView Earnings Details
8/29/2013Q3 2013$0.51$0.53$183.50 million$185.40 millionViewListenView Earnings Details
6/6/2013Q2 2013$0.41$0.41$176.04 million$176.50 millionViewListenView Earnings Details
2/28/2013Q1 2013$0.28$0.31$165.44 million$161.30 millionViewListenView Earnings Details
12/6/20120.46$0.46$175.46 millionViewListenView Earnings Details
8/30/2012Q312$0.43$0.45$0.17 million$0.17 millionViewN/AView Earnings Details
6/7/2012$0.32$0.33ViewN/AView Earnings Details
3/1/2012$0.21$0.26ViewN/AView Earnings Details
12/8/2011$0.35$0.37ViewN/AView Earnings Details
8/25/2011$0.34$0.36ViewN/AView Earnings Details
5/26/2011$0.24$0.26ViewN/AView Earnings Details
3/3/2011$0.17$0.28ViewN/AView Earnings Details
12/16/2010$0.30$0.31$124.19 million$126.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Reference Laboratories (NASDAQ:BRLI)
Current Year EPS Consensus Estimate: $1.98 EPS
Next Year EPS Consensus Estimate: $2.31 EPS

Dividends

Dividend History for Bio-Reference Laboratories (NASDAQ:BRLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Reference Laboratories (NASDAQ:BRLI)
Insider Trades by Quarter for Bio-Reference Laboratories (NASDAQ:BRLI)
Insider Trades by Quarter for Bio-Reference Laboratories (NASDAQ:BRLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2013Howard DubinettCOOSell20,000$29.40$588,000.00View SEC Filing  
6/27/2013Sam SingerCFOSell4,000$28.95$115,800.00View SEC Filing  
6/26/2013Sam SingerCFOSell6,000$28.50$171,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bio-Reference Laboratories (NASDAQ:BRLI)
Latest Headlines for Bio-Reference Laboratories (NASDAQ:BRLI)
Source:

Social

Bio-Reference Laboratories (BRLI) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff